Pyxis MICVO Data Mature: 39% cORR, 9.2-Month mDOR, 81% 12-Month OS in 2L+ HNSCC
PYXS sits 46% above its 52-week low of $1.03.
Summary
Updated Phase 1 MICVO data in 2L+ head and neck cancer show a 39% confirmed response rate, 9.2-month median duration of response and 81% 12-month survival probability, with neuropathy resolving and a Phase 3 planned for mid-2027.
Key Events · Product Development and Regulatory · PYXS
-
MICVO Response Rate Rises to 39%
Confirmed ORR reached 39% (13 of 33 evaluable patients) at the October 14, 2026 cutoff, up from 36% in the prior readout, with 94% disease control and 52% confirmed-plus-unconfirmed ORR.
-
Responses Last 9.2 Months
Newly reported median duration of response is 9.2 months, and median PFS of 6.7 months compares with 4.2 months on patients' most recent prior therapy — a 50% improvement per the company.
-
Survival and Safety Improve
12-month overall survival probability is 81% with only 6 of 33 deaths; all six Grade 3 peripheral neuropathy cases resolved or are resolving, and capped-dose patients saw 0% Grade 3 neuropathy versus 67% above the cap.
-
Phase 3 Slated for Mid-2027
The randomized Headliner SM trial (~500 patients, MICVO vs investigator's choice) is planned to start mid-2027, with regulatory feedback expected in the first quarter of 2027 and more mature OS data in the first half of 2027.
Analysis · PYXS · Life Sciences
MICVO is improving with time, not fading: at the October 14, 2026 cutoff, confirmed response rate rose to 39% from 36%, median PFS extended to 6.7 months from 6.2, and 12-month survival probability improved to 81% from 79%. For a head-and-neck cancer drug, the newly reported 9.2-month median duration of response is the number that matters most — responses are lasting — and median PFS of 6.7 months compares with 4.2 months on patients' most recent prior therapy. Safety also improved: all six Grade 3 peripheral neuropathy cases resolved or are resolving, and capped-dose patients had zero Grade 3 neuropathy versus 67% above the cap. This is the dataset the company will take into a ~500-patient randomized Phase 3 (Headliner SM) planned for mid-2027, with regulatory feedback expected in the first quarter of 2027 and more mature OS in the first half of 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYXS was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $168.6M. The 52-week trading range was $1.03 to $5.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.